Nature Medicine, Published online: 07 February 2025; doi:10.1038/s41591-025-03495-z
In a first-in-human phase 1 trial, HER2-specific CAR macrophages were feasible to manufacture and well tolerated, with no dose-limiting toxicities in patients with HER2-overexpressing solid tumors.
